We currently think of the HER2 status of breast cancers in a binary fashion. So HER2-positive breast cancers are sensitive and respond to HER2 targeted therapies, whereas HER2-negative breast cancers do not. But we know within the HER2-negative population, there are tumors that express low levels of HER2, and this low level of HER2 can be targeted with some of our newer-generation antibody drug conjugates. And in the DESTINY-Breast04 trial I think we've shown for the first time now that a HER2 targeted therapy, trastuzumab deruxtecan, can improve the outcomes and survival for patients with HER2-low metastatic breast cancer. And so, the results of this trial really allow us to extend the benefits of HER2 targeted therapy to a whole new population of patients and improve, I think, survival outcomes for a subpopulation of patients with metastatic breast cancer.